Pembrolizumab-induced thrombotic thrombocytopenic purpura

Introduction Pembrolizumab is a humanised monoclonal antibody targeting the receptor programmed cell death protein-1 (PD-1), with anti-tumour activity demonstrated for many malignancies. Such immune checkpoint inhibitors are associated with many immune-related adverse events including rash, colitis,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of oncology pharmacy practice 2020-07, Vol.26 (5), p.1237-1240
Hauptverfasser:	Dickey, Marcus SR, Raina, Anant J, Gilbar, Peter J, Wisniowski, Brendan L, Collins, Joel T, Karki, Bhaskar, Nguyen, Andrew DK
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - adverse effects Antineoplastic Agents, Immunological - adverse effects Apoptosis Autoantibodies Autoimmune diseases Carcinoma, Non-Small-Cell Lung - diagnosis Carcinoma, Non-Small-Cell Lung - drug therapy Cell death Colitis Endocrine disorders Female Health risk assessment Hemolytic anemia Hepatitis Humans Immune checkpoint inhibitors Immunotherapy Lung cancer Lung Neoplasms - diagnosis Lung Neoplasms - drug therapy Metastases Methylprednisolone Middle Aged Monoclonal antibodies Non-small cell lung carcinoma PD-1 protein Pembrolizumab Plasma Exchange - methods Pneumonitis Prednisolone Purpura Purpura, Thrombotic Thrombocytopenic - chemically induced Purpura, Thrombotic Thrombocytopenic - diagnosis Purpura, Thrombotic Thrombocytopenic - therapy Small cell lung carcinoma Targeted cancer therapy Thrombocytopenia Thrombocytopenic purpura Thrombotic thrombocytopenic purpura Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!